Ikena Oncology nominates IK-595 as first RAS pathway candidate; IND targeted H2 2023

ImageneBio, Inc.

IK-595: MEK-RAF complex inhibitor traps MEK & RAF in inactive complex, aims to avoid resistance.
Discontinuing IK-007 (EP4 antagonist) internal development; exploring strategic alternatives.
Cash runway extended into 2025; does not include potential IK-175 opt-in fees from BMS.
IK-930 TEAD inhibitor monotherapy initial clinical data expected H2 2023; osimertinib combo starts H1 2023.
Preclinical differentiation data for IK-595 planned for H1 2023; RAS pathway implicated in >500K US cancer cases/yr.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.